Epacadostat plus pembrolizumab versus placebo plus pembrolizumab as first-line treatment for metastatic non-small cell lung cancer with high levels of programmed death-ligand 1: a randomized, double-blind phase 2 study

  1. Tokito, T.
  2. Kolesnik, O.
  3. Sørensen, J.
  4. Artac, M.
  5. Quintela, M.L.
  6. Lee, J.-S.
  7. Hussein, M.
  8. Pless, M.
  9. Paz-Ares, L.
  10. Leopold, L.
  11. Daniel, J.
  12. Munteanu, M.
  13. Samkari, A.
  14. Xu, L.
  15. Butts, C.
Revista:
BMC Cancer

ISSN: 1471-2407

Any de publicació: 2024

Volum: 23

Número: Suppl 1

Tipus: Article

DOI: 10.1186/S12885-023-11203-8 GOOGLE SCHOLAR lock_openAccés obert editor
Font de les dades: Scopus